Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06058546 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis

StatusUnknown
PhasePhase 2
Started2023-11-23
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 3, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2026-09-06
Trial status changed: Recruiting → Unknown
2024-08-29
Not Yet Recruiting→Recruiting Study Identification, Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Unknown
Start dateestimated 2023-10→confirmed 2023-11-23
Study sitesdetails revised at 12 of 12 sites
2023-09-27
Study Status, Outcome Measures, Eligibility v1
Eligibility criteria-10 characters
[...] ned with non-plaque Psoriasis at screening (such as guttate, reverse, arthropathica, pustular, erythrodermic and other types of Ps [...]
Secondary endpointsdetails revised at 5 of 11 entries
2023-09-21
Original filing
This study will evaluate the efficacy and safety of Jiuweihuaban Pill in the treatment of moderate to severe plaque psoriasis(syndrome of blood-heat ).
Trial Details
NCT Number NCT06058546
Lead Sponsor Tasly Pharmaceutical Group Co., Ltd
Conditions Plaque Psoriasis
Enrollment 180 participants
Start Date 2023-11-23
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2024-09-03